High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era

Neuro-Oncology

Volumn 15, Issue 1, 2013, Pages 104-111

  Patil, Chirag G ^a   Nuño, Miriam ^a   Elramsisy, Adam ^a   Mukherjee, Debraj ^a   Carico, Christine ^a   Dantis, Jocelynn ^a   Hu, Jethro ^a   Yu, John S ^a   Fan, Xuemo ^a   Black, Keith L ^a   Bannykh, Serguei I ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

EGFR; glioblastoma multiforme (GBM); IDH1; MGMT; overall survival; p MAPK; PTEN

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84871977089     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos272     Document Type: Article

References (21)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine. 2005;352:987-996. (Pubitemid 40349501)
4. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-1068.
5. Aeder SE, Martin PM, Soh JW, Hussaini IM. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene. 2004;23:9062-9069. (Pubitemid 40013073)
6. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Research. 2000;20:2761-2771. (Pubitemid 30614496)
7. Lakka SS, Jasti SL, Gondi C, et al. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene. 2002;21:5601-5608. (Pubitemid 34983550)
8. Nakada M, Kita D, Watanabe T, et al. Aberrant Signaling Pathways in Glioma. Cancers. 2011;3:3242-3278.
9. Park MJ, Park IC, Hur JH, et al. Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogenactivated protein kinase. Journal of Neurosurgery. 2002;97: 112-118.
10. Van Brocklyn J, Letterle C, Snyder P, Prior T. Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta. Cancer Letters. 2002;181:195-204. (Pubitemid 34518304)
11. Mawrin C, Diete S, Treuheit T, et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol. 2003;23: 641-648.
12. Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2006;12:3935-3941. (Pubitemid 44078078)
13. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol. 2006;65:1181-1188. (Pubitemid 44885942)
14. Poulogiannis G, Luo F, Arends MJ. RAS signalling in the colorectum in health and disease. Cell Communication & Adhesion. 2012;19(1):1-9.
15. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 1997;15:2755-2765. (Pubitemid 28004565)
16. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol. 2004;108:467-470. (Pubitemid 39534587)
17. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263-1284. (Pubitemid 47125967)
18. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 2001;61:6674-6678. (Pubitemid 32896484)
19. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991;51:2164-2172.
20. Traverse S, Seedorf K, Paterson H, Marshall CJ, Cohen P, Ullrich A. EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor. Curr Biol. 1994;4:694-701.
21. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signalregulated kinase-and protein kinase B-mediated signalling pathways. The Biochemical Journal. 2002;365:119-126. (Pubitemid 34756146)